These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34797554)

  • 1. Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases.
    Sakai T; Mori C; Koshiba H; Yuminaga R; Tanabe K; Ohtsu F
    Drugs Real World Outcomes; 2022 Mar; 9(1):43-51. PubMed ID: 34797554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.
    Wu SN; Huang C; Wang YQ; Li X; Zhang SQ; Chen XD; Qin DY; Zhu L; Wen JY; Luo NC; Hu J; Liu Z
    Ther Adv Drug Saf; 2024; 15():20420986241285929. PubMed ID: 39429679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
    Ohyama K; Kawakami H; Inoue M
    Biol Pharm Bull; 2017; 40(5):616-620. PubMed ID: 28458346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Reye's syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis.
    Matsumoto K; Hasegawa S; Nakao S; Shimada K; Mukai R; Tanaka M; Satake R; Yoshida Y; Goto F; Inoue M; Ikesue H; Iguchi K; Hashida T; Nakamura M
    SAGE Open Med; 2020; 8():2050312120974176. PubMed ID: 33282307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
    Inoue K; Shiokawa M; Wakakura M; Tomita G
    J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database.
    Sakai T; Ohtsu F; Mori C; Tanabe K; Goto N
    Drug Saf; 2017 Nov; 40(11):1141-1146. PubMed ID: 28664356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.
    Sakai T; Mori C; Ohtsu F
    Front Pharmacol; 2022; 13():1063625. PubMed ID: 36438807
    [No Abstract]   [Full Text] [Related]  

  • 8. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
    Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
    Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Vestergaard Kvist A; Faruque J; Vallejo-Yagüe E; Weiler S; Winter EM; Burden AM
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33924496
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
    Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
    Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database.
    Kurian A; Kaushik K; Subeesh V; Maheswari E; Kunnavil R
    J Reprod Infertil; 2018; 19(3):152-156. PubMed ID: 30167396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System.
    Yang R; Yin N; Zhao Y; Li D; Zhang X; Li X; Zhang Y; Faiola F
    Front Pharmacol; 2021; 12():772768. PubMed ID: 35046808
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis.
    Yang XT; Zhao L; Wang LJ; Zhang Y; Liao DY; Wang JM
    Int J Ophthalmol; 2020; 13(3):474-480. PubMed ID: 32309186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
    Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P
    ScientificWorldJournal; 2012; 2012():804730. PubMed ID: 22606063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
    Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
    Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.